Favorable Outcome of COVID-19 Infection in a Pediatric Cancer Patient Receiving an Anti-PD-L1/Anti-CTLA-4 Combination.

Revon-Riviere, Gabriel; Soler, Christine; Andrianarivony, Tina; Fily, Sarah; André, Nicolas

Revon-Riviere, Gabriel; Soler, Christine; Andrianarivony, Tina; Fily, Sarah; André, Nicolas.

Revon-Riviere G; Department of Pediatric Oncology & Hematology.
Soler C; Marseille Early Phases Cancer Trials Center CLIP², Aix Marseille University APHM, Marseille.
Andrianarivony T; Hematology Department, Hôpital l'Archet CHU de Nice, Nice, France.
Fily S; Department of Pediatric Oncology & Hematology.
André N; Department of Pediatric Oncology & Hematology.

J Pediatr Hematol Oncol ; 43(7): e1045-e1046, 2021 10 01.

Article in English | MEDLINE | ID: covidwho-1165548

Subject(s)

B7-H1 Antigen/antagonists & inhibitors; COVID-19/complications; CTLA-4 Antigen/antagonists & inhibitors; Immune Checkpoint Inhibitors/therapeutic use; Neoplasms/drug therapy; SARS-CoV-2/isolation & purification; Adolescent; COVID-19/transmission; COVID-19/virology; Humans; Male; Neoplasms/diagnosis; Neoplasms/virology; Prognosis

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: B7-H1 Antigen / CTLA-4 Antigen / Immune Checkpoint Inhibitors / SARS-CoV-2 / COVID-19 / Neoplasms Type of study: Case report / Diagnostic study / Prognostic study Topics: Long Covid Limits: Adolescent / Humans / Male Language: English Journal: J Pediatr Hematol Oncol Journal subject: Hematology / Neoplasms / Pediatrics Year: 2021 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google